(Q40131701)

17 September 2017

title

Projecting future drug expenditures--2008. (English)

1 reference

17 September 2017

8

Glen T Schumock

1 reference

17 September 2017

James M Hoffman

1

1 reference

17 September 2017

Nilay D Shah

2

1 reference

17 September 2017

Lee C Vermeulen

3

1 reference

17 September 2017

Fred Doloresco

4

1 reference

17 September 2017

Penny Grim

5

1 reference

17 September 2017

Robert J Hunkler

6

1 reference

17 September 2017

Karrie M Hontz

7

1 reference

17 September 2017

publication date

1 February 2008

1 reference

American Journal of Health-System Pharmacy

17 September 2017

published in

1 reference

17 September 2017

volume

65

1 reference

17 September 2017

issue

3

1 reference

17 September 2017

page(s)

234-253

1 reference

Projecting future drug expenditures--2007.

17 September 2017

cites work

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Health spending projections through 2016: modest changes obscure part D's impact

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

National health spending in 2005: the slowdown continues

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Health benefits in 2007: premium increases fall to an eight-year low, while offer rates and enrollment remain stable

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

The effect of population aging on future hospital demand

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

The demise of the blockbuster?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

31 March 2020

When the party's over

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Efficacy and safety of torcetrapib, a novel cholesteryl ester transfer protein inhibitor, in individuals with below-average high-density lipoprotein cholesterol levels on a background of atorvastatin

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

"Me-too" products--friend or foe?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Sidelining safety--the FDA's inadequate response to the IOM.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Drug safety reform at the FDA--pendulum swing or systematic improvement?

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Rosiglitazone--continued uncertainty about safety

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Rosiglitazone and cardiotoxicity--weighing the evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

The record on rosiglitazone and the risk of myocardial infarction

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Rosiglitazone: a thunderstorm from scarce and fragile data

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Warning flags for erythropoiesis-stimulating agents and cancer-associated anemia

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Correction of anemia with epoetin alfa in chronic kidney disease

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Randomized, double-blind, placebo-controlled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Recombinant human erythropoietins and cancer patients: updated meta-analysis of 57 studies including 9353 patients

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Pharmacy considerations for the use of IGIV therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Clinical and investigational considerations for the use of IGIV therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Projecting future drug expenditures--2006.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Potential savings from substituting generic drugs for brand-name drugs: medical expenditure panel survey, 1997-2000.

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Regulation of follow-on biologics

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Generic biologics may be coming to the marketplace if legislation passes in Congress

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Managing wholesaler agreements in the fee-for-service era

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Infantile spasms: therapy and outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Implications of the specialty drug marketplace for health-system pharmacy: a roundtable discussion

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

Management of chronic diseases in the 21st century: the emerging role of specialty pharmacies

31 March 2020

1 reference

https://api.crossref.org/works/10.2146%2FAJHP070629

31 March 2020

Identifiers

DOI

10.2146/AJHP070629

1 reference

17 September 2017

1 reference